TY - JOUR
T1 - Nationwide Prospective Cohort Study on Cataract Surgery With Multifocal Intraocular Lens Implantation in Japan
AU - Survey Working Group of the Japanese Society of Cataract and Refractive Surgery
AU - Negishi, Kazuno
AU - Hayashi, Ken
AU - Kamiya, Kazutaka
AU - Sato, Masaki
AU - Bissen-Miyajima, Hiroko
N1 - Funding Information:
Funding/Support: None. Financial Disclosures: Kazuno Negishi reports grants from Fuji Xerox Co (Tokyo, Japan) and outside the submitted work; grants and personal fees from Alcon Japan Ltd (Tokyo, Japan), Santen Pharmaceutical (Osaka, Japan), HOYA Corporation (Tokyo, Japan), Abbott Medical Optics Inc (Santa Ana, California, USA), Senju Pharmaceutical (Osaka, Japan), and Kowa Company (Nagoya, Japan), outside the submitted work; personal fees and/or nonfinancial support from RE Medical Inc (Osaka, Japan), B.L.J. Company, Ltd (Tokyo, Japan), Wakamoto (Tokyo, Japan), Universal View Co, Ltd (Tokyo, Japan), M3, Inc (Tokyo, Japan), Toray Industries (Tokyo, Japan), Chuo Sangio Company (Hyogo, Japan), Kowa Pharmaceutical Company Ltd (Tokyo, Japan), Otsuka Pharmaceutical (Tokyo, Japan), Qualitas, Inc (Tokyo, Japan), NIDEK Co, Ltd (Aichi, Japan), and Carl Zeiss Meditec Co, Ltd (Tokyo, Japan), outside the submitted work; and is in the process of applying for a patent (PCT/JP2015/65997) for potential products for myopia suppression outside the submitted work. Kazutaka Kamiya reports personal fees from STAAR Surgical, Carl Zeiss Meditec Co, Ltd (Tokyo, Japan), Santen Pharmaceutical (Osaka, Japan), Senjyu Pharmaceutical (Osaka, Japan), AMO (Santa Ana, California, USA), Kowa Company (Nagoya, Japan), and Otsuka Pharmaceutical (Tokyo, Japan); and grants from Alcon Japan Ltd (Tokyo, Japan) and Novaritis (Tokyo, Japan), outside the submitted work. Hiroko Bissen-Miyajima reports personal fees from Alcon Japan Ltd (Tokyo, Japan), Johnson & Johnson Surgical Vision (Santa Ana, California, USA), Zeiss (Jena, Germany), Santen Pharmaceutical (Osaka, Japan), and HOYA Corporation (Tokyo, Japan), outside the submitted work. The remaining authors have no financial disclosures. All authors attest that they meet the current ICMJE criteria for authorship.
Funding Information:
Funding/Support: None. Financial Disclosures: Kazuno Negishi reports grants from Fuji Xerox Co (Tokyo, Japan) and outside the submitted work; grants and personal fees from Alcon Japan Ltd (Tokyo, Japan), Santen Pharmaceutical (Osaka, Japan), HOYA Corporation (Tokyo, Japan), Abbott Medical Optics Inc (Santa Ana, California, USA), Senju Pharmaceutical (Osaka, Japan), and Kowa Company (Nagoya, Japan), outside the submitted work; personal fees and/or nonfinancial support from RE Medical Inc (Osaka, Japan), B.L.J. Company, Ltd (Tokyo, Japan), Wakamoto (Tokyo, Japan), Universal View Co, Ltd (Tokyo, Japan), M3, Inc (Tokyo, Japan), Toray Industries (Tokyo, Japan), Chuo Sangio Company (Hyogo, Japan), Kowa Pharmaceutical Company Ltd (Tokyo, Japan), Otsuka Pharmaceutical (Tokyo, Japan), Qualitas, Inc (Tokyo, Japan), NIDEK Co, Ltd (Aichi, Japan), and Carl Zeiss Meditec Co, Ltd (Tokyo, Japan), outside the submitted work; and is in the process of applying for a patent (PCT/JP2015/65997) for potential products for myopia suppression outside the submitted work. Kazutaka Kamiya reports personal fees from STAAR Surgical, Carl Zeiss Meditec Co, Ltd (Tokyo, Japan), Santen Pharmaceutical (Osaka, Japan), Senjyu Pharmaceutical (Osaka, Japan), AMO (Santa Ana, California, USA), Kowa Company (Nagoya, Japan), and Otsuka Pharmaceutical (Tokyo, Japan); and grants from Alcon Japan Ltd (Tokyo, Japan) and Novaritis (Tokyo, Japan), outside the submitted work. Hiroko Bissen-Miyajima reports personal fees from Alcon Japan Ltd (Tokyo, Japan), Johnson & Johnson Surgical Vision (Santa Ana, California, USA), Zeiss (Jena, Germany), Santen Pharmaceutical (Osaka, Japan), and HOYA Corporation (Tokyo, Japan), outside the submitted work. The remaining authors have no financial disclosures. All authors attest that they meet the current ICMJE criteria for authorship. Acknowledgements: We are grateful to 2 statisticians, Mr Ryota Ishii and Dr Ryo Takemura (Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital) for providing valuable advice regarding the statistical analysis. We are also grateful to Ms Sachiko Masui (Department of Ophthalmology, Keio University School of Medicine) for assistance with the statistical analysis. We thank Ms Lynda Charters for English editing.
Publisher Copyright:
© 2019 The Authors
PY - 2019/12
Y1 - 2019/12
N2 - Purpose: To conduct a nationwide prospective cohort study of multifocal intraocular lens (mfIOL) implantation to determine clinical outcomes and patient satisfaction and assess factors affecting patient satisfaction. Design: Prospective, multicenter cohort study. Methods: Setting: institutional; patient population: a total of 1051 consecutive patients (1631 eyes) who underwent cataract surgery with mfIOL implantation at 65 Japanese institutions from January 2017 to June 2018. The inclusion criteria were patient age of 20 years and older and cataract surgery with mfIOL implantation. The exclusion criteria were the absence of informed consent, completed postoperative questionnaires, and no record of the IOL models implanted. Observation procedures: the uncorrected and corrected distance visual acuities (UDVAs and CDVAs) at 5 m; uncorrected VAs at 50, 40, and 30 cm; and questionnaires regarding subjective visual symptoms, spectacle independence, and surgical satisfaction were assessed 3 months postoperatively. Main outcome measure: odds ratios for the overall surgical satisfaction were computed for the preoperative/postoperative factors. Results: We analyzed data from 1384 eyes of 871 patients. The UDVAs and CDVAs, respectively, improved significantly at 3 months postoperatively. The intermediate and near VAs varied with the IOL models; 68.4% of patients were almost or totally spectacle-independent; 3.9% of patients reported surgical dissatisfaction. In patients implanted bilaterally with the same mfIOLs, postoperative blurred vision and/or decreased contrast was the most important factor in the overall surgical satisfaction. Conclusions: MfIOLs provided good visual outcomes and high satisfaction rates in this large patient cohort. The difference in the outcomes with the extended depth-of-focus IOLs did not differ significantly from the bifocal IOLs. The postoperative blurred vision is important to the overall surgical satisfaction.
AB - Purpose: To conduct a nationwide prospective cohort study of multifocal intraocular lens (mfIOL) implantation to determine clinical outcomes and patient satisfaction and assess factors affecting patient satisfaction. Design: Prospective, multicenter cohort study. Methods: Setting: institutional; patient population: a total of 1051 consecutive patients (1631 eyes) who underwent cataract surgery with mfIOL implantation at 65 Japanese institutions from January 2017 to June 2018. The inclusion criteria were patient age of 20 years and older and cataract surgery with mfIOL implantation. The exclusion criteria were the absence of informed consent, completed postoperative questionnaires, and no record of the IOL models implanted. Observation procedures: the uncorrected and corrected distance visual acuities (UDVAs and CDVAs) at 5 m; uncorrected VAs at 50, 40, and 30 cm; and questionnaires regarding subjective visual symptoms, spectacle independence, and surgical satisfaction were assessed 3 months postoperatively. Main outcome measure: odds ratios for the overall surgical satisfaction were computed for the preoperative/postoperative factors. Results: We analyzed data from 1384 eyes of 871 patients. The UDVAs and CDVAs, respectively, improved significantly at 3 months postoperatively. The intermediate and near VAs varied with the IOL models; 68.4% of patients were almost or totally spectacle-independent; 3.9% of patients reported surgical dissatisfaction. In patients implanted bilaterally with the same mfIOLs, postoperative blurred vision and/or decreased contrast was the most important factor in the overall surgical satisfaction. Conclusions: MfIOLs provided good visual outcomes and high satisfaction rates in this large patient cohort. The difference in the outcomes with the extended depth-of-focus IOLs did not differ significantly from the bifocal IOLs. The postoperative blurred vision is important to the overall surgical satisfaction.
UR - http://www.scopus.com/inward/record.url?scp=85071951944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071951944&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2019.07.019
DO - 10.1016/j.ajo.2019.07.019
M3 - Article
C2 - 31377282
AN - SCOPUS:85071951944
SN - 0002-9394
VL - 208
SP - 133
EP - 144
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
ER -